Escherichia Coli Infections Clinical Trial
Official title:
Effects of Nutritional Fat on the Growth of Intestinal E. Coli
Recent experiments in the lab of Prof. WD Hardt revealed, that in mice, 24 h exposure to a
high-fat diet results in a breakdown of colonization resistance against Salmonella
typhimurium. Mechanistic experiments identified bile acids as the mediator for reduced
colonization resistance. Exposure to a high fat diet leads to increased bile acid secretion
which in turn modify the intestinal microbiota.
It is now the aim to verify the results of this study in human healthy volunteers. The
nutritional habits of all participants will carefully be evaluated. In the intervention
phase, participants will be exposed to either high-fat or low-fat diet and a controlled dose
of the non-pathogenic bacteria E. coli Nissle. E. coli Nissle is the active compound for
"Mutaflor®" and other probiotics.
It is planned to enumerate E. coli Nissle counts in the stool after Mutaflor ingestion and to
quantify other changes of the human microbiota. The hypothesis is that a high-fat diet leads
to increased bile acid secretion results in favorable growth conditions for E. coli Nissle,
resulting in high bacterial counts in the stool.
Infectious diarrhea causes substantial morbidity in Western countries and the developing
world and leads to the use of considerable health resources. Antibiotic resistance continues
to increase, potentially leading to a decrease in therapeutic options in the future.
Important pathogens include Salmonella typhimurium (S. typhimurium) and pathogenic
Escherichia coli (E. coli) which are genetically closely related.
The human intestine has considerable colonization resistance against bacterial pathogens.
This resistance is largely mediated by the gut microbiota. Therefore, previous exposure to
antibiotics or immunosuppression leading to a breakdown of the intestinal defense systems
increase the risk for subsequent infection with S. typhimurium.
The composition of the human microbiome undergoes dramatic changes upon exposure to various
factors including nutrition, physical activity, drugs and much more. Most studies focused on
long-term exposure to various factors; however, since bacterial growth is rapid (doubling
time of S. typhimurium under optimal conditions = 20min), even short-term variations in the
environment could dramatically influence the human microbiota.
In the lab of Prof. WD Hardt, a mouse model of S. typhimurium enterocolitis has been
established. Since most mouse strains are resistant against colonization with S. typhimurium,
pretreatment with antibiotics is a requirement for induction of S. typhimurium enterolitis.
However, recent experiments in the Hardt lab revealed, that in mice, 24 h exposure to a
high-fat diet also results in a breakdown of colonization resistance, leading to Salmonella
enterocolitis upon S. typhimurium infection. The same is true for E. coli strains. Subsequent
experiments demonstrated that exposure to fatty acids is sufficient to overcome colonization
resistance. Mechanistic experiments identified fat-elicited bile-release as the underlying
mechanism: Exposure to a high fat diet leads to increased bile acid secretion; S. typhimurium
can tolerate 10-fold higher bile acid concentrations than commensal bacterial, leading to a
growth advantage of S. typhimurium compared to competing bacteria (WD Hardt et al.,
unpublished data).
The aim of this study is to verify the results of this study in human healthy volunteers. The
nutritional habits of all participants will be carefully evaluated. In the intervention
phase, participants will be exposed to either high-fat or low-fat diet and a controlled dose
of the non-pathogenic bacteria E. coli Nissle. E. coli Nissle is the active compound for
"Mutaflor®" and other probiotics. E. coli Nissle has therapeutic effects for the treatment of
chronic inflammatory intestinal diseases. In contrast to other non-pathogenic E. coli
strains, it exhibits a specific pattern of fitness factors but lacks prominent virulence
factors. In vivo and in vitro experiments demonstrated both, protective effects against
infection with intestinal pathogens as well as potent immunomodulatory properties. Growth of
E. coli Nissle in the human gut resembles growth of S. typhimurium. Both bacteriae also share
metabolic requirements for intestinal growth. Therefore, growth E. coli Nissle in the human
intestine can be used as a marker for growth of E. coli strains, Salmonella typhimurium and
related pathogens.
It is planned to enumerate E. coli Nissle counts in the stool after Mutaflor ingestion and to
quantify other changes of the human microbiota. The hypothesize is that a high-fat diet,
leading to increased bile acid secretion results in favorable growth conditions for E. coli
Nissle, resulting in high bacterial counts in the stool.
The results of the study will help improving the understanding of the consequences of
nutritional composition on the vulnerability of the human organism to bacterial infections.
Such an improved understanding might enable designing preventive measures for the growth of
unwanted E. coli strains (e.g. ESBL, pathogenic) or S. typhimurium infection and/ or a severe
disease course and might ultimately help limiting antibiotic use and the evolution of
antibiotic resistant pathogens.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT03303937 -
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
|
N/A | |
Not yet recruiting |
NCT03869593 -
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
|
||
Completed |
NCT02853708 -
Epidemiology of ST131 in Besançon University Hospital
|
N/A | |
Active, not recruiting |
NCT02729116 -
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01324726 -
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
|
N/A | |
Completed |
NCT01406288 -
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
|
N/A | |
Completed |
NCT00167986 -
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
|
Phase 4 | |
Terminated |
NCT00362869 -
Enteroaggregative E.Coli (EAEC)
|
Phase 1 | |
Completed |
NCT00167999 -
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
|
Phase 4 | |
Completed |
NCT06252428 -
Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals
|